On June 29, 2022, ReCode Therapeutics, a genetic medicines company using superior delivery to power the next wave of messenger RNA (mRNA) and gene correction therapeutics, announced an additional $120 million in Series B financing, co-led by new investors Leaps by Bayer, the impact investment unit of Bayer AG, and AyurMaya, an affiliate of Matrix Capital Management, with participation from Amgen Ventures. Notably, with the additional $120 million in new financing, ReCode Therapeutics has secured a total of $200 million in Series B funding. Wilson Sonsini Goodrich & Rosati represented ReCode Therapeutics in the transaction.

The new investment will expand and diversify ReCode Therapeutics’ platform and pipeline to include mRNA and gene correction therapeutics for lung, liver, and central nervous system diseases. The initial $80 million Series B funding was completed in October 2021.

The Wilson Sonsini team that led the transaction includes:

Corporate
Ken Clark
Michael Coke
Christina Poulsen
Eric Abram
Jacie Valentine
Jennifer Gu

Patents and Innovations
Vern Norviel
Ali Alemozafar
Uale Taotafa
Vishakha Negi

Technology Transactions
Lowell Segal

For more information, please see ReCode Therapeutics’ news release. Additional coverage can be found on San Francisco Business Times and Fierce Biotech.